Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
Kus T, Aktas G, Sevinc A, Kalender ME, Camci C
Unlike other targeted tyrosine kinase inhibitors, data on erlotinib do not indicate that is is associated with increased acute cardiovascular event (ACE) risk.
Despite not being a cardiotoxic drug itself, preclinical studies suggest an aggregate effect of erlotinib on ACE, This article presents two non-small-cell lung cancer cases that developed ACE under erlotinib treatment.
© All rights reserved
fonte foto: https://en.wikipedia.org/wiki/Erlotinib